Tedizolid (0.25 μg/mL) inhibits all 28 clinical isolates of PRSP which is 4-fold more potent than linezolid against PRSP[1].

The tedizolid phosphate at a minimum total daily dose of 10 mg/kg achieved a 100% survival rate for mice infected with PSSP type III. Lungs of infected mice treated with tedizolid phosphate show less severe inflammation and edema, as indicated by the mean scores for inflammation and edema[1].